Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

featured

Published in Obesity, Metabolic Syndrome, and Prediabetes

Expert Opinion / Interview · August 27, 2018

Type 2 Diabetes and Fatty Liver/Non-alcoholic Steatohepatitis

Interview by

Jason Sloane MD

Interview with

Richard E. Pratley MD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Disclosures

Disclosure statements are available on the authors' profiles:

Richard Pratley MD

story of the week

Once-Weekly Semaglutide in Individuals With Obesity and Knee Osteoarthritis

N. Engl. J. Med · November 18, 2024
story of the week

Associations of Diabetes and Prediabetes With Mortality and Life Expectancy in Chinese Individuals

Diabetes Care · November 16, 2024

updated
story of the week

The Burden of Diabetes-Associated Multiple Long-Term Conditions on Years of Life Spent and Lost

Nat. Med. · November 04, 2024
story of the week

Impact of GLP-1 Receptor Agonist–Based Treatments on Fat-Free Mass

Diabetes Obes Metab · November 01, 2024

updated
story of the week

Association Between Ultraprocessed Food Consumption and the Risk of Diabetes

Diabetologia · October 21, 2024
story of the week

Association of Glycaemic Risk Factors and Diabetes Duration With the Risk of Heart Failure in People With Type 2 Diabetes

Diabetes Obes Metab · October 14, 2024
story of the week

Outcomes of Time-Restricted Eating in Adults With Metabolic Syndrome

Ann. Intern. Med · October 09, 2024
story of the week

Impact of Overweight and Obesity on Health Outcomes in the US From 1990 to 2021

Diabetes Obes Metab · October 07, 2024
story of the week

The Effect of Semaglutide on Mortality and COVID-19–Related Deaths

J Am Coll Cardiol · October 07, 2024
story of the week

Impact of GLP-1 RAs on Cardiorenal Outcomes and Mortality in People With Type 2 Diabetes and Acute Kidney Disease

Nat Commun · September 30, 2024

updated
story of the week

SGLT2 Inhibitors in Hospitalised Patients With COVID-19

Lancet Diabetes Endocrinol · September 30, 2024

Obesity, Metabolic Syndrome, and Prediabetes

Type 2 Diabetes and Fatty Liver/Non-alcoholic Steatohepatitis

Additional Info

Further Reading

Once-Weekly Semaglutide in Individuals With Obesity and Knee Osteoarthritis

Associations of Diabetes and Prediabetes With Mortality and Life Expectancy in Chinese Individuals

The Burden of Diabetes-Associated Multiple Long-Term Conditions on Years of Life Spent and Lost

Impact of GLP-1 Receptor Agonist–Based Treatments on Fat-Free Mass

Association Between Ultraprocessed Food Consumption and the Risk of Diabetes

Association of Glycaemic Risk Factors and Diabetes Duration With the Risk of Heart Failure in People With Type 2 Diabetes

Outcomes of Time-Restricted Eating in Adults With Metabolic Syndrome

Impact of Overweight and Obesity on Health Outcomes in the US From 1990 to 2021

The Effect of Semaglutide on Mortality and COVID-19–Related Deaths

Impact of GLP-1 RAs on Cardiorenal Outcomes and Mortality in People With Type 2 Diabetes and Acute Kidney Disease

SGLT2 Inhibitors in Hospitalised Patients With COVID-19

Related Videos